Publications by authors named "Gilad Alon"
Background: Heated intraperitoneal chemotherapy (HIPEC) was shown to induce immunogenicity of peritoneal metastases from colorectal cancer (PM-CRC) by induction of immunogenic cell death. We aimed to explore whether the addition of a checkpoint inhibitor would augment the effect of HIPEC in an experimental murine model of PM-CRC.
Methods: PM-CRC was established in C57BL mice by intraperitoneal inoculation of MC38 colon cancer cells.
Article Synopsis
- HIPEC is a treatment for peritoneal metastases from colorectal cancer, but its effectiveness is debated due to high recurrence rates.
- The study tested thymosin alpha 1 (Tα1) as an adjuvant to improve HIPEC outcomes in a mouse model, finding that Tα1 significantly increased survival rates without directly inhibiting tumor growth.
- Tα1 enhanced the anti-tumor immune response by promoting a T helper (Th) 1 response and increasing CD8 T cell infiltration, suggesting potential for immunomodulatory treatments alongside HIPEC.